An experimental drug in early development
for aggressive brain tumors can cross the blood - brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).
Therefore, researchers are aggressively looking to find new molecular targets
for this aggressive brain tumor.
Not exact matches
Several studies have supported a role
for cancer stem cells in the
aggressive brain tumors called glioblastoma, but those studies involved inducing human
tumors to grow in mice, and as such their relevance to cancer in humans has been questioned.
Glioblastoma is the most
aggressive type of
tumor that originates in the
brain and with no curative treatments currently available, the average survival time
for patients ranges from 15 to 18 months.
Findings published in Oncotarget offer new hope
for children with highly
aggressive brain tumors like atypical teratoid / rhabdoid
tumor (AT / RT) and medulloblastoma.